Julie Tibbets > Goodwin > Washington DC, United States > Lawyer Profile
Goodwin Offices

901 NEW YORK AVENUE, NW
WASHINGTON DC 20001
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Julie Tibbets

Position
Partner
Career
Julie Tibbets is a partner in Goodwin’s Technology and Life Sciences group and a member of its FDA practice.
Ms. Tibbets focuses her practice on FDA-regulated product development, marketing and corporate communications as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product areas of focus include biologics, drugs, medical devices, in vitro diagnostics, lab-developed tests, as well as digital health tools and apps. Ms. Tibbets advises clients on product development strategy, interactions with the FDA, clinical trial documentation, adverse event reporting, commercial strategy, product labeling and advertising. She also leads the regulatory due diligence reviews of FDA-regulated M&A or investment targets, potential collaborators and licensees, and guides the regulatory disclosures of FDA-regulated entities in their initial public offerings. Ms. Tibbets also works closely with the Food + Healthy Living practice team at Goodwin on the intersection of food, supplement and cosmetic regulation with FDA’s drug and device authorities.
Education
J.D., 2004 University of North Carolina, Chapel Hill B.A., 2001 Purdue University (Highest Honors)
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Healthcare > Service providers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- M&A/corporate and commercial > Shareholder activism